Peer-influenced content. Sources you trust. No registration required. This is HCN.

CRC: Collected Highlights with Commentary from ASCO 2021

At this year’s ASCO annual meeting, CRC management insights were revealed in several abstract presentations covering pembrolizumab, regorafenib, immunotherapies, trifluridine/tipiracil plus bevacizumab, and an antibody-drug conjugate targeting HER2.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form